Wednesday, March 7, 2012

ALS MND Daily News Digest

EMA grants CK-2017357 orphan medicinal product designation
Pharmaceutical Business Review
Cytokinetics' fast skeletal muscle troponin activator CK-2017357 has been granted orphan medicinal product designation by European Medicines Agency (EMA), for the treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig's ...
See all stories on this topic »
Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
Sacramento Bee
Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA. In addition to ALS, the company is also ...
See all stories on this topic »

No comments:

Post a Comment